Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
2607.HK Stock Summary
Top 10 Correlated ETFs
2607.HK
In the News
2607.HK Financial details
Company Rating
Strong Buy
Market Cap
57.95B
Income
4.6B
Revenue
254.88B
Book val./share
18.72
Cash/share
11.11
Dividend
0.66
Dividend %
5.9%
Employees
47.88K
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
8.33
Forward P/E
5.51
PEG
-2.81
P/S
0.22
P/B
0.56
P/C
1.02
P/FCF
13.27
Quick Ratio
1.05
Current Ratio
1.34
Debt / Equity
0.68
LT Debt / Equity
0.11
-
-
EPS (TTM)
1.26
EPS next Y
2.06
EPS next Q
0.6
EPS this Y
-10.06%
EPS next Y
63.7%
EPS next 5Y
63.7%
EPS last 5Y
3.28%
Revenue last 5Y
7.84%
Revenue Q/Q
-2.18%
EPS Q/Q
6.67%
-
-
-
-
SMA20
-6.33%
SMA50
3.36%
SMA100
3.27%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
7%
ROC
0.09%
Gross Margin
12%
Oper. Margin
3%
Profit Margin
2%
Payout
87%
Shs Outstand
4.84B
Shs Float
3.68B
-
-
-
-
Target Price
-
52W Range
10.32-16.6
52W High
-29%
52W Low
+13.6%
RSI
39.23
Rel Volume
0.72
Avg Volume
2.23M
Volume
1.61M
Perf Week
-2.24%
Perf Month
-0.7%
Perf Quarter
-2.24%
Perf Half Y
-8.97%
-
-
-
-
Beta
0.252
-
-
Volatility
0.24%, 0.39%
Prev Close
-1.56%
Price
11.36
Change
-1.22%
2607.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 56.23 | 65.83 | 67.52 | 75.94 | 66.61 | |
Net income per share | 1.37 | 1.44 | 1.58 | 1.79 | 1.61 | |
Operating cash flow per share | 1.11 | 2.13 | 2.41 | 1.78 | 1.36 | |
Free cash flow per share | 0.42 | 1.15 | 1.35 | 0.33 | 0.59 | |
Cash per share | 6.1 | 5.92 | 7.41 | 7.44 | 10.63 | |
Book value per share | 13.79 | 14.7 | 15.96 | 17.37 | 19.26 | |
Tangible book value per share | 10.89 | 12.16 | 13.36 | 14.61 | 17.25 | |
Share holders equity per share | 13.79 | 14.7 | 15.96 | 17.37 | 19.26 | |
Interest debt per share | 11.62 | 12.71 | 11.68 | 11.68 | 11.56 | |
Market cap | 39.53B | 38.36B | 32.57B | 34.28B | 39.92B | |
Enterprise value | 52.49B | 54.83B | 42.07B | 43.58B | 51.08B | |
P/E ratio | 10.18 | 9.4 | 7.24 | 6.73 | 7.11 | |
Price to sales ratio | 0.25 | 0.21 | 0.17 | 0.16 | 0.17 | |
POCF ratio | 12.61 | 6.37 | 4.76 | 6.77 | 8.42 | |
PFCF ratio | 33.16 | 11.73 | 8.49 | 36.37 | 19.39 | |
P/B Ratio | 1.01 | 0.92 | 0.72 | 0.69 | 0.6 | |
PTB ratio | 1.01 | 0.92 | 0.72 | 0.69 | 0.6 | |
EV to sales | 0.33 | 0.29 | 0.22 | 0.2 | 0.22 | |
Enterprise value over EBITDA | 5.97 | 5.07 | 3.63 | 3.64 | 4.25 | |
EV to operating cash flow | 16.74 | 9.1 | 6.15 | 8.61 | 10.77 | |
EV to free cash flow | 44.03 | 16.77 | 10.97 | 46.24 | 24.81 | |
Earnings yield | 0.1 | 0.11 | 0.14 | 0.15 | 0.14 | |
Free cash flow yield | 0.03 | 0.09 | 0.12 | 0.03 | 0.05 | |
Debt to equity | 0.81 | 0.83 | 0.7 | 0.64 | 0.58 | |
Debt to assets | 0.25 | 0.25 | 0.21 | 0.19 | 0.19 | |
Net debt to EBITDA | 1.48 | 1.52 | 0.82 | 0.78 | 0.93 | |
Current ratio | 1.36 | 1.31 | 1.22 | 1.27 | 1.35 | |
Interest coverage | 4.32 | 6.35 | 5.09 | 5.4 | 5.34 | |
Income quality | 0.7 | 1.25 | 1.22 | 0.81 | 0.68 | |
Dividend Yield | 0.06 | 0.07 | 0.07 | 0.08 | 0.08 | |
Payout ratio | 0.61 | 0.63 | 0.54 | 0.53 | 0.55 | |
Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Intangibles to total assets | 0.12 | 0.11 | 0.11 | 0.11 | 0.09 | |
Capex to operating cash flow | -0.62 | -0.46 | -0.44 | -0.81 | -0.57 | |
Capex to revenue | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | |
Capex to depreciation | -1.66 | -1.46 | -1.41 | -1.92 | -1.21 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 20.63 | 21.82 | 23.83 | 26.46 | 26.43 | |
ROIC | 0.06 | 0.09 | 0.07 | 0.08 | 0.07 | |
Return on tangible assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
Graham Net | -5.1 | -6.34 | -5.77 | -7.13 | -2.42 | |
Working capital | 24.57B | 23.48B | 19.43B | 24.67B | 38.82B | |
Tangible asset value | 30.8B | 34.45B | 37.98B | 41.52B | 60.08B | |
Net current asset value | 12.83B | 10.45B | 13.12B | 12.13B | 29.38B | |
Invested capital | 0.81 | 0.83 | 0.7 | 0.64 | 0.58 | |
Average receivables | 41.87B | 51.13B | 56.93B | 62.9B | 71.26B | |
Average payables | 31.22B | 36.01B | 37.33B | 39.89B | 46.78B | |
Average inventory | 21.15B | 24.95B | 24.48B | 25.6B | 30.78B | |
Days sales outstanding | 110.88 | 105.54 | 113.97 | 111.43 | 120.58 | |
Days payables outstanding | 93.97 | 84.25 | 83.87 | 81.85 | 93.41 | |
Days of inventory on hand | 66.9 | 56.84 | 53.46 | 52.82 | 62.42 | |
Receivables turnover | 3.29 | 3.46 | 3.2 | 3.28 | 3.03 | |
Payables turnover | 3.88 | 4.33 | 4.35 | 4.46 | 3.91 | |
Inventory turnover | 5.46 | 6.42 | 6.83 | 6.91 | 5.85 | |
ROE | 0.1 | 0.1 | 0.1 | 0.1 | 0.08 | |
Capex per share | -0.69 | -0.97 | -1.06 | -1.45 | -0.77 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 22.12 | 16.44 | 17.91 | 17.95 | 17.74 | |
Net income per share | 0.39 | 0.23 | 0.41 | 0.3 | 0.32 | |
Operating cash flow per share | 0.39 | 0.23 | 0.41 | 1.15 | 0.18 | |
Free cash flow per share | 0.07 | 0.02 | 0.22 | 0.93 | -0.03 | |
Cash per share | 13.39 | 10.61 | 10.3 | 11.57 | 11.11 | |
Book value per share | 23.27 | 19.22 | 18.54 | 18.22 | 18.72 | |
Tangible book value per share | 20.83 | 17.22 | 16.79 | 16.52 | 17.05 | |
Share holders equity per share | 23.27 | 19.22 | 18.54 | 18.22 | 18.72 | |
Interest debt per share | 14.02 | 11.18 | 12.15 | 12.61 | 12.93 | |
Market cap | 27.93B | 39.99B | 47.34B | 53.02B | 41.67B | |
Enterprise value | 41.91B | 51.15B | 64.74B | 67.84B | 59.23B | |
P/E ratio | 6.24 | 12.45 | 7.8 | 12.14 | 8.78 | |
Price to sales ratio | 0.44 | 0.7 | 0.71 | 0.8 | 0.64 | |
POCF ratio | 24.98 | 49.79 | 31.19 | 12.44 | 62.76 | |
PFCF ratio | 147.66 | 551.27 | 57.34 | 15.37 | -356.66 | |
P/B Ratio | 0.42 | 0.6 | 0.69 | 0.79 | 0.61 | |
PTB ratio | 0.42 | 0.6 | 0.69 | 0.79 | 0.61 | |
EV to sales | 0.67 | 0.89 | 0.98 | 1.02 | 0.91 | |
Enterprise value over EBITDA | 19.22 | 23.07 | 21.06 | 24.94 | 26.37 | |
EV to operating cash flow | 37.48 | 63.68 | 42.66 | 15.92 | 89.2 | |
EV to free cash flow | 221.54 | 705.11 | 78.42 | 19.66 | -506.93 | |
Earnings yield | 0.04 | 0.02 | 0.03 | 0.02 | 0.03 | |
Free cash flow yield | 0.01 | 0 | 0.02 | 0.07 | 0 | |
Debt to equity | 0.6 | 0.58 | 0.65 | 0.69 | 0.68 | |
Debt to assets | 0.2 | 0.19 | 0.22 | 0.22 | 0.22 | |
Net debt to EBITDA | 6.41 | 5.03 | 5.66 | 5.45 | 7.82 | |
Current ratio | 1.37 | 1.35 | 1.38 | 1.33 | 1.34 | |
Interest coverage | 4.65 | 3.03 | 5.06 | 4.39 | 4.01 | |
Income quality | 1 | 1 | 1 | 3.9 | 0.56 | |
Dividend Yield | 0.07 | 0.01 | 0.01 | 0.01 | 0.07 | |
Payout ratio | 1.78 | 0.42 | 0.42 | 0.25 | 2.3 | |
Sales general and administrative to revenue | 0.05 | -0.04 | 0.02 | -0.01 | 0.05 | |
Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Intangibles to total assets | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | |
Capex to operating cash flow | -0.83 | -0.91 | -0.46 | -0.19 | -1.18 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | 0.84 | -0.36 | 0 | -0.81 | 0.78 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 14.35 | 9.98 | 13.08 | 11 | 11.69 | |
ROIC | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
Return on tangible assets | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
Graham Net | -1.98 | -2.41 | -2.04 | -2.53 | -2.44 | |
Working capital | 40.08B | 38.82B | 42.87B | 40.44B | 42.2B | |
Tangible asset value | 59.22B | 60.08B | 62.1B | 61.07B | 62.4B | |
Net current asset value | 29.47B | 29.38B | 31.02B | 30.41B | 31.63B | |
Invested capital | 0.6 | 0.58 | 0.65 | 0.69 | 0.68 | |
Average receivables | 77.12B | 78.41B | 81.28B | 86.75B | 87.72B | |
Average payables | 46.99B | 50.39B | 52.54B | 54.84B | 57.54B | |
Average inventory | 28.05B | 31.41B | 33.3B | 32.65B | 34.1B | |
Days sales outstanding | 114.72 | 120.22 | 116.76 | 118.77 | 121.8 | |
Days payables outstanding | 80.17 | 93.64 | 83.62 | 87.24 | 91.39 | |
Days of inventory on hand | 46.18 | 62.58 | 50.24 | 51.49 | 54.37 | |
Receivables turnover | 0.78 | 0.75 | 0.77 | 0.76 | 0.74 | |
Payables turnover | 1.12 | 0.96 | 1.08 | 1.03 | 0.98 | |
Inventory turnover | 1.95 | 1.44 | 1.79 | 1.75 | 1.66 | |
ROE | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
Capex per share | -0.33 | -0.21 | -0.19 | -0.22 | -0.21 |
2607.HK Frequently Asked Questions
What is Shanghai Pharmaceuticals Holding Co., Ltd stock symbol ?
Shanghai Pharmaceuticals Holding Co., Ltd is a CN stock and trading under the symbol 2607.HK
What is Shanghai Pharmaceuticals Holding Co., Ltd stock quote today ?
Shanghai Pharmaceuticals Holding Co., Ltd stock price is $11.36 today.
Is Shanghai Pharmaceuticals Holding Co., Ltd stock public?
Yes, Shanghai Pharmaceuticals Holding Co., Ltd is a publicly traded company.